Jennifer T Mcdevitt

US Patent:

20130330353, Dec 12, 2013

Filed:

Nov 15, 2011

Appl. No.:

13/884843

Inventors:

Jaye Viner - Gaithersburg MD, US
Yong Chang - Gaithersburg MD, US
Jennifer McDevitt - Gaithersburg MD, US

Assignee:

MEDIMMUNE, LLC - Gaithersburg MD

International Classification:

A61K 39/395

US Classification:

4241451, 4241581

Abstract:

Without limitation, this disclosure relates to methods of treating cell proliferation disorders, neoplastic disorders, cancers, tumors and the like using anti-IGF antibodies, or antigen binding fragments thereof. Disclosed herein are methods of treating cancer in a patient, for example a human patient, comprising administering to the patient at least two doses of an antibody which binds both IGF-I and/or IGF-II. The doses are separated by about a week, or by about three weeks, and each dose comprises an amount of antibody greater than about 0.5 mg kg of patient body mass and less than about 50 mg per kg of patient body mass.

US Patent:

20150183860, Jul 2, 2015

Filed:

Mar 13, 2015

Appl. No.:

14/657134

Inventors:

- GAITHERSBURG MD, US
Yong Chang - Gaithersburg MD, US
Jennifer McDevitt - Gaithersburg MD, US

International Classification:

C07K 16/22

Abstract:

Without limitation, this disclosure relates to methods of treating cell proliferation disorders, neoplastic disorders, cancers, tumors and the like using anti-IGF antibodies, or antigen binding fragments thereof. Disclosed herein are methods of treating cancer in a patient, for example a human patient, comprising administering to the patient at least two doses of an antibody which binds both IGF-I and/or IGF-II. The doses are separated by about a week, or by about three weeks, and each dose comprises an amount of antibody greater than about 0.5 mg kg of patient body mass and less than about 50 mg per kg of patient body mass.